Sugi Predict

Sugi Predict / Compounds / Exelixis

Exelixis

Exelixis

SCHEMBL371899

COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c2cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 13/20 1.00
▸ AXL P30530 10/20 1.00
▸ KDR P35968 6/20 1.00
▸ MERTK Q12866 6/20 0.87
▸ FLT3 P36888 4/20 0.81
▸ AURKB Q96GD4 4/20 0.81
▸ RET P07949 3/20 0.81
▸ KIT P10721 3/20 0.81
▸ FLT1 P17948 3/20 0.81
▸ AURKA O14965 2/20 0.81
▸ RIPK2 O43353 2/20 0.81
▸ ABL1 P00519 2/20 0.81
▸ EGFR P00533 2/20 0.81
▸ ERBB2 P04626 2/20 0.81
▸ NTRK1 P04629 2/20 0.81
▸ LCK P06239 2/20 0.81
▸ LYN P07948 2/20 0.81
▸ HCK P08631 2/20 0.81
▸ ADRA2A P08913 2/20 0.81
▸ BCR P11274 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Exelixis SCHEMBL29693473 1.00 MET (1.00) METAXLKDRMERTKFLT3
SCHEMBL24413668 0.94 MET (0.89) METAXLKDRMERTKFLT3
SCHEMBL24414026 0.94 MET (0.89) METAXLKDRMERTKFLT3
SCHEMBL372296 0.94 AXL (0.88) METAXLKDRMERTKFLT3
SCHEMBL29693516 0.94 AXL (0.88) METAXLKDRMERTKFLT3
SCHEMBL29693534 0.94 AXL (0.88) METAXLKDRMERTKFLT3
SCHEMBL4401190 0.94 AXL (0.88) METAXLKDRMERTKFLT3
SCHEMBL29693431 0.94 AXL (0.88) METAXLKDRMERTKFLT3
SCHEMBL19373358 0.94 MET (0.88) METAXLKDRMERTKFLT3
SCHEMBL24451294 0.93 MET (0.87) METAXLKDRMERTKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115885035-A Method for purifying cardiomyocytes 千纸鹤治疗公司 2023-03-31 — — CN claimed
EP-3329918-B1 C-MET MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2022-05-25 — — EP claimed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 — — US claimed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 — — US claimed
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
EP-3329918-A2 C-MET MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2018-06-06 — — EP claimed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 — — US claimed
EP-2409704-B1 c-Met modulators and methods of use EXELIXIS INC (US) 2017-09-20 — — EP claimed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 — — US claimed
US-20150376133-A1 C-Met Modulators and Methods of Use EXELIXIS, INC. 2015-12-31 — — US claimed
US-20140155396-A1 C-Met Modulators and Method of Use EXELIXIS, INC. 2014-06-05 — — US claimed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 — — US claimed
EP-2409704-A2 c-Met modulators and methods of use Exelixis Inc. (US) 2012-01-25 — — EP claimed
US-20230136878-A1 CARDIOMYOCYTE PURIFICATION METHOD Orizuru Therapeutics, Inc. (JP) 2023-05-04 — — US disclosed
CN-115885035-A Method for purifying cardiomyocytes 千纸鹤治疗公司 2023-03-31 — — CN disclosed
US-20220184090-A1 COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE NOVARTIS AG (CH) 2022-06-16 — — US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-20220184090-A1 COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE EGFR, ERBB2, ERBB3 MET 4/4885AXL 26/4885KDR 62/4885
US-20140155396-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-20150376133-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET MET 3/4885AXL 109/4885KDR 4/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885AXL 241/4885KDR 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.